Literature DB >> 17126291

A transgenic rat with the human ATTR V30M: a novel tool for analyses of ATTR metabolisms.

Mitsuharu Ueda1, Yukio Ando, Yoji Hakamata, Masaaki Nakamura, Taro Yamashita, Konen Obayashi, Shingo Himeno, Seiichiro Inoue, Yuki Sato, Takashi Kaneko, Nobutoki Takamune, Shogo Misumi, Shozo Shoji, Makoto Uchino, Eiji Kobayashi.   

Abstract

Amyloidogenic transthyretin (ATTR) is the pathogenic protein of familial amyloidotic polyneuropathy (FAP). To establish a tool for analyses of ATTR metabolisms including after liver transplantations, we developed a transgenic rat model expressing human ATTR V30M and confirmed expressions of human ATTR V30M in various tissues. Mass spectrometry for purified TTR revealed that rat intrinsic TTR and human ATTR V30M formed tetramers. Congo red staining and immunohistochemistry revealed that nonfibrillar deposits of human ATTR V30M, but not amyloid deposits, were detected in the gastrointestinal tracts of the transgenic rats. At 24h after liver transplantation, serum human ATTR V30M levels in transgenic rats that received livers from normal rats became lower than detectable levels. These results thus suggest that this transgenic rat may be a useful animal model which analyzes the metabolism of human ATTR V30M including liver transplantation studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17126291     DOI: 10.1016/j.bbrc.2006.11.045

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Novel Antibody for the Treatment of Transthyretin Amyloidosis.

Authors:  Akihiko Hosoi; Yu Su; Masaharu Torikai; Hirofumi Jono; Daisuke Ishikawa; Kenji Soejima; Hirofumi Higuchi; Jianying Guo; Mitsuharu Ueda; Genki Suenaga; Hiroaki Motokawa; Tokunori Ikeda; Satoru Senju; Toshihiro Nakashima; Yukio Ando
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

Review 2.  Animal models of human amyloidoses: are transgenic mice worth the time and trouble?

Authors:  Joel N Buxbaum
Journal:  FEBS Lett       Date:  2009-07-20       Impact factor: 4.124

Review 3.  Transthyretin-related familial amyloidotic polyneuropathy-Progress in Kumamoto, Japan (1967-2010)-.

Authors:  Shukuro Araki; Yukio Ando
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

4.  A new in vivo analysis model to detect sexually dimorphic rat liver cytochrome P450 gene expression dependent on growth hormone secretory patterns.

Authors:  Motoyo Maruyama; Masahiko Fujisawa; Makoto Yokosuka; Toru R Saito; Shin-Ichi Hayama; Toshio Akimoto; Yoji Hakamata
Journal:  Exp Anim       Date:  2016-06-29

5.  Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening.

Authors:  Yukimoto Tsuda; Kunitoshi Yamanaka; Risa Toyoshima; Mitsuharu Ueda; Teruaki Masuda; Yohei Misumi; Teru Ogura; Yukio Ando
Journal:  Sci Rep       Date:  2018-12-14       Impact factor: 4.379

6.  Curcumin promotes AApoAII amyloidosis and peroxisome proliferation in mice by activating the PPARα signaling pathway.

Authors:  Jian Dai; Ying Li; Fuyuki Kametani; Xiaoran Cui; Yuichi Igarashi; Jia Huo; Hiroki Miyahara; Masayuki Mori; Keiichi Higuchi
Journal:  Elife       Date:  2021-01-26       Impact factor: 8.140

Review 7.  Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies.

Authors:  Haruki Koike; Masahisa Katsuno
Journal:  Neurol Ther       Date:  2020-09-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.